Pfizer’s Q4 and full-year earnings report beat analysts’ expectations, but its guidance for this year disappointed investors. The company predicted little to no revenue growth in 2019 due to Viagra losing patent protection and Lyrica expected to face competition from generics. (CNBC)

Aetna is working with Apple to develop an Apple Watch app that takes a users’ medical history into account to set personalized health and wellness goals, the CVS Health division said on Tuesday. Known as Attain, the app will reward users for meeting activity goals and completing tasks. (Reuters)

What do the next five years have in store for the pharma industry? Three areas to watch will be pricing, biosimilars, and speciality medicines, according to a report from IQVIA. The report predicted that while global spending on medicine could exceed $1.5 trillion by 2023, compared with $1.2 trillion in 2018, annual growth could drop from 6% annually over the past five years to 3% to 6% annual growth. (MM&M)

Takeda said on Tuesday that its dengue vaccine met the main goals of its late-stage clinical trial, meeting its main benchmarks of safely and effectively treating the mosquito-borne illness. The company also said that no safety concerns have emerged about the treatment. (Reuters)

Federal prosecutors accused the founder of Insys Therapeutics of running a “criminal enterprise” driven by greed in the first day of trial on Monday. Founder John Kapoor, who has been accused of bribing doctors to prescribe his fentanyl spray, is the first pharma executive to face trial amid the opioid epidemic. (Associated Press)